Joachim Kreuzburg, Rainer Lehmann, René Fáber Sartorius | Sartorius Stedim Biotech | July 21, 2023
H1 2023 overview
Temporary weak demand continued throughout Q2; customers signal re-ordering to start from late Q3 onwards
Underlying EBITDA margin at robust level of ~30%; cost containment measures in place, managing delivery ability remains key
Revised outlook 2023 confirmed
Polyplus acquisition closed; start of integration; bond issuance in preparation
2
Agenda
Sartorius Group
H1 2023 results | FY 2023 guidance
Sartorius Stedim Biotech Group
H1 2023 results | FY 2023 guidance
Questions & Answers
3
Sartorius Group
Expected soft top line development; margin remains on robust level
Sartorius Group
H1 2022
H1 2023
in %
in % cc1
in millions of € unless otherwise specified
Sales revenue
2,060
1,735
-15.8
-15.4
Order intake
2,169
1,450
-33.2
-32.7
Underlying EBITDA2
697
517
-25.9
Underlying EBITDA2 margin in %
33.9
29.8
-4.1pp
Underlying EPS3 (ord.) in €
4.88
2.95
-39.4
Underlying EPS3 (pref.) in €
4.89
2.96
-39.3
Marginal Covid-related business; excluding this effect, sales decline in the upper single-digit percentage range
OI strongly affected by destocking and low investment activities of customers
Underlying EBITDA margin in line with expectations and on a decent level considering lower volumes
1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate
4
Sartorius Group
Navigating through volatility: Temporary decline in perspective
vs. H1 19
vs. H1 20
Sales revenue
+94%
+64%
Order intake
+49%
+16%
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
Q2
2019
2020
2021
2022
2023
Sales ex Covid
Covid-19-related sales
Order intake
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sartorius Stedim Biotech SA published this content on 21 July 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 July 2023 14:19:10 UTC.
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically.
For next generation processes, Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of turning science into solutions on a daily basis.
With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany.
SARTORIUS STEDIM BIOTECH 
